• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

{Delta}9-TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPAR{gamma} DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE
Conclusions Even though 9–THC and pioglitazone are both protective against MPP+ only 9–THC induces PPAR dependent mitochondrial biogenesis, a mechanism that may be beneficial for the treatment of PD.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Zeissler, M.-L., Eastwood, J., Oliver Hanemann, C., Zajicek, J., Carroll, C. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Parkinson's disease, Stroke Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23-24 October 2013 Source Type: research

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Publication date: Available online 23 June 2015 Source:The Lancet Neurology Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg...
Source: The Lancet Neurology - June 24, 2015 Category: Neurology Source Type: research